Short-term Efficacy Observation of Intravenous Administration of Cinobufalin Combined with Lenvastinib in the Treatment of Primary Liver Cancer Patients After TACE
WANG Ying-dong, DING Hai-bin, HUANG Zi-chao, et al
Abdominal Tumor Surgery,Shaanxi Cancer Hospital,Xi'an Shaanxi 710061
Abstract：【Objective】To investigate the short-term efficacy of intravenous administration of bufalin combined with lenvastinib in the treatment of primary liver cancer (PLC) after transarterial chemoembolization (TACE). 【Methods】A total of 104 patients with PLC after TACE were randomly divided into the observation group and the control group, with 52 cases in each group. The control group was treated with lumphatinib, while the observation group was given intravenous administration of bufalin in addition to the control group. The therapeutic effect was evaluated after 4 months of continuous treatment and followed up for 12 months. The short-term anti-tumor efficacy, the changes of immune function and tumor markers before and after treatment, the safety and survival status of the two groups at 12 months were compared between the two groups. 【Results】The clinical control rate of the observation group was higher than that of the control group (P<0.05). After treatment, the levels of Th1/Th2 in the observation group were higher than those before treatment(P<0.05), while the levels of Th17/Treg in the observation group were lower than those before treatment(P<0.05). However, the levels of Th1/Th2 in the control group were lower than those before treatment (P<0.05) and levels of Th17/Treg in the control group were higher than those before treatment(P<0.05). The Th1/Th2 level of the observation group was higher than that in the control group (P<0.05), and Th17/Treg level in the observation group was lower than that in the control group (P<0.05). After treatment, levels of CEA and AFP in both groups were lower than those before treatment (P<0.05), and CEA and AFP levels in the observation group were lower than those in the control group (P<0.05). There was no significant difference in CEA and AFP levels between the two groups before treatment (P>0.05). The safety in the two groups were not significantly different (P>0.05). Also, there was no significant difference in the incidence of various adverse reactions between the two groups (P>0.05). The survival rate of the control group at 12 months was 70.59%, and survival rate of the observation group was 80.77%. There was no statistically significant difference in the survival curve between the two groups (P>0.05). 【Conclusion】The intravenous injection of cinnobufacin combined with lenvatinib in the treatment of PLC after TACE can effectively improve the short-term treatment efficacy, improve immune function, reduce the level of tumor markers and is well tolerated.
王颖栋, 丁海斌, 黄子超, 朱金祥, 郭甲民. 华蟾素联合仑伐替尼治疗经动脉化疗栓塞术后原发性肝癌患者的近期疗效[J]. 医学临床研究, 2022, 39(1): 9-12.
WANG Ying-dong, DING Hai-bin, HUANG Zi-chao, et al. Short-term Efficacy Observation of Intravenous Administration of Cinobufalin Combined with Lenvastinib in the Treatment of Primary Liver Cancer Patients After TACE. JOURNAL OF CLINICAL RESEARCH, 2022, 39(1): 9-12.
[1] TAYLOR A C, MADDIRELA D, WHITE S B. Role of radioembolization for biliary tract and primary liver cancer[J].Surg Oncol Clin N Am,2019, 28(4):731-743.
[2] LEE Y T, TAN Y J, OON C E. Molecular targeted therapy: Treating cancer with specificity[J].Eur J Pharmacol,2018, 834(5):188-196.
[3] DENG X, SHENG J, LIU H, et al. Cinobufagin promotes cell cycle arrest and apoptosis to block human esophageal squamous cell carcinoma cells growth via the p73 signalling pathway[J].Biol Pharm Bull,2019, 42(9):1500-1509.
[4] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版)[J].中华消化外科杂志, 2017, 16(7):635-647.
[5] EISERNHAUER E A. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009, 45(2):1-247.
[6] BOYD M R, PAULL K D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen[J].Drug Development Res,2010,34(2):91-109.
[7] TAYLOR A C, MADDIRELA D, WHITE S B. Role of radioembolization for biliary tract and primary liver cancer[J].Surg Oncol Clin N Am,2019, 28(4):731-743.
[8] 袁冰, 王燕, 张金龙, 等. 仑伐替尼治疗经肝动脉化疗栓塞术无效的中晚期肝细胞癌患者的临床观察[J].中华医学杂志, 2020, 100(11):833-836.
[9] 尹彩星, 司海超, 范兆阳, 等. 右美托咪定对肝癌根治术患者Th1,Th2,Th17,Treg细胞及相关细胞因子的影响[J].广东医学, 2019, 40(24):98-102.
[10] LIN W, NIU Z, ZHANG H, et al. Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer[J].Int J Clin Exp Pathol,2019, 12(9):3604-3612.
[11] 李楠静.华蟾素对人胃癌SGC7901细胞增殖及Rho GTPase表达的影响[J].重庆医学, 2018, 47(23):12-14.
2022, Vol. 39 
